To amend the Internal Revenue Code of 1986 to extend the deduction for certain expenses of elementary and secondary school teachers.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2012 · first_quarter · Pharmacy
S. 1882, the FAIR Generics Act S. 27, the Preserve Access to Affordable Pharmaceuticals Act HR 3995, the Protecting Consumer Access to Generic Drugs Act S. 296, HR 2245, The Preserving Access to Life Savings Medications Act HR 4332, the Generic Drug Application Review Fairness Act HR 3998, Generic Drug and Biosimilar User Fee Act HR 2182, S. 1734, the Generating Antibiotic Incentives Now Act Amending Section 505(j) of the Food, Drug, and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclaims seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications Supreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceuticals Industries, Ltd. Prospective legislation establishing a generic drug user fee program Prospective legislation establishing a biosimilar user fee program Establishment of a federal track and trace system for pharmaceuticals The use of Risk Evaluation Mitigation Strategies (REMS) programs by brand drug companies to delay generic competition International Nonproprietary Names for Biosimilars
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $200,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Health Issues
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Client expense: $700,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE